Clinical trials: Dermatitis, active
Solid Cancer, Gastric (Cardia, Body) Cancer
Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form.
- Conditions
- Solid Cancer, Gastric (Cardia, Body) Cancer, Esophageal Cancer, Colorectal Cancer (CRC)
- Trial name
- ESCAPE (NCT07114627)
- Testing
- Blood sampling for pharmacokinetics
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- Erasmus Medical Center
Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab
Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus and recurrence of eczematous eruptions. Evaluation of response to treatment are only clinical using Eczema Area Severity Index (EASI), SCOring of Atopic…
- Trial name
- NEMOSKIN (NCT07730788)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Hôpitaux Drôme Nord
Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema
Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
A Phase 2b study investigating the efficacy of zabalafin in people with mild to moderate atopic dermatitis (eczema).
- Conditions
- Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema, Atopic Dermatitis, Atopic Dermatitis (AD)
- Trial name
- CLEAR-AD1 (NCT06855745)
- Testing
- zabalafin
- Where
- 12 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Alphyn Biologics
Atopic Dermatitis
Changes in Skin Myco- and Microbiome After Lebrikizumab Treatment
The goal of this observational study is to characterize the skin myco- and microbiome of patients with atopic dermatitis before and after initiation of treatment with lebrikizumab.
- Trial name
- NCT07807228
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Eczema/Atopic Dermatitis, Otitis Externa
Nigella Sativa Oil for Eczematous Otitis Externa
Eczematous otitis externa is a common inflammatory condition of the external auditory canal characterized by itching, discomfort, discharge, and pain.
- Trial name
- NCT07525505
- Testing
- Mometasone Furoate (MF), Nigella sativa oil
- Where
- Turkey (Türkiye)
- Volunteers
- 85 people
- Sponsor
- Bezmialem Vakif University
Atopic Dermatitis (AD), Atopic Eczema
Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema
This randomized controlled trial (RCT) aims to evaluate the efficacy and safety of Crisaborole 2% cream compared with placebo in patients with mild to moderate atopic dermatitis (AD), also known as atopic eczema.
- Trial name
- CRISA-AD (NCT07438509)
- Testing
- Crisaborole 2% Cream
- Volunteers
- 270 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Psoriasis (PsO), Vitiligo Vulgaris
Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis
Primary objective: The primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis…
- Conditions
- Psoriasis (PsO), Vitiligo Vulgaris, Atopic Dermatitis, Areata Alopecia
- Trial name
- STIGMADERM (NCT06801821)
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Atopic Dermatitis
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06807281
- Testing
- Abrocitinib
- Where
- 40 sites in United States, China and 5 more
- Volunteers
- 450 people
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema Atopic Dermatitis
Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective
This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.
- Conditions
- Atopic Dermatitis, Eczema Atopic Dermatitis, Eczema, Caregiver
- Trial name
- NCT07323394
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- PeriPharm
Immune Checkpoint Inhibitor-Induced Dermatitis
JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis
Currently, the principal strategy for immune checkpoint inhibitors (ICI)-related dermatitis include systemic use of corticosteroids, which can impair the efficacy of preceding ICIs treatment.
- Trial name
- NCT07530224
- Testing
- treated with JAK inhibitors orally for 28 days
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shixiu Wu
Atopic Dermatitis, Eczema
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADorable-1 (NCT05559359)
- Testing
- Lebrikizumab, Topical Corticosteroid (TCS)
- Where
- 85 sites in United States, Argentina and 10 more
- Volunteers
- 377 people
- Sponsor
- Eli Lilly and Company
Atopic Eczema
A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema
A 4 week, open label, multi-centre (GP setting), post market clinical follow-up study with Doublebase Once in patients of any age and any severity of atopic eczema.
- Trial name
- NCT06453512
- Testing
- Doublebase Once
- Where
- United Kingdom
- Volunteers
- 65 people
- Sponsor
- Dermal Laboratories Ltd
Atopic Dermatitis (AD)
A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
- Trial name
- NCT07544862
- Testing
- Stapokibart
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chengdu Kangnuoxing Biopharma,Inc.
Lichen Simplex Chronicus
A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants.
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of multiple ascending oral doses(MAD) of PG-033 by directly comparing it with placebo.
- Trial name
- NCT07619183
- Testing
- PG-033 tablets
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Eczema, Asthma
The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants
This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and…
- Conditions
- Eczema, Asthma, Allergy;Food
- Trial name
- PEBBLES (NCT03667651)
- Testing
- EpiCeram
- Where
- 4 sites in Australia
- Volunteers
- 760 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Seborrheic Dermatitis
The Effectiveness of Itraconazole Pulse Therapy vs Topical 2% Ketoconazole in the Treatment of Moderate to Severe Seborrheic Dermatitis of Scalp.
This study is a randomized controlled trial comparing the effectiveness of oral itraconazole pulse therapy versus topical 2% ketoconazole shampoo in treating moderate to severe scalp seborrheic dermatitis (SD).
- Trial name
- NCT07734441
- Testing
- Itraconazole (200 mg), Ketoconazole 2%
- Where
- Pakistan
- Volunteers
- 80 people
- Sponsor
- Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan
Asthma, Asthma in Children
Allergy, Asthma, and Atopic Eczema in Finland
The summary is available at --> https://www.finnatopy.fi/summary
- Conditions
- Asthma, Asthma in Children, Allergy, Rhinitis, Allergic
- Trial name
- FinnATOPY (NCT06330974)
- Testing
- No intervention, No Intervention: Observational Cohort
- Where
- Finland
- Volunteers
- 1,600,000 people
- Sponsor
- Tampere University
Atopic Dermatitis
A Study of TAVO101 in Atopic Dermatitis Patients
This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with moderate and severe AD.
- Trial name
- NCT06176040
- Testing
- TAVO101
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Tavotek Biotherapeutics
Atopic Dermatitis
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
This is a first-in-human (FIH) study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of GLR2053 in healthy male and female adult participants, and to evaluate the effect of a…
- Trial name
- NCT07920783
- Testing
- GLR2053 Tablets
- Where
- China
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Breast Cancer, Radio Dermatitis
Photobiomodulation in Radiodermatitis in People With Breast Cancer
Most breast cancer patients undergoing radiotherapy develop radiodermatitis, making it one of the most prevalent adverse events during cancer treatment.
- Trial name
- NCT06990165
- Testing
- Photobiomodulation
- Where
- 2 sites in Brazil
- Volunteers
- 148 people
- Sponsor
- Instituto Nacional de Cancer, Brazil